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This study was suppor
tional Research Foundahe aim of this study was to investigate whether the heart rate-corrected QT (QTc) interval on the electrocardiogram
(ECG) is associated with the onset of atrial ﬁbrillation (AF).Background Patients with hereditary short-QT or long-QT syndromes, representing the very extremes of the QT interval, both
seem to have a high prevalence of AF.Methods A total of 281,277 subjects were included, corresponding to one-third of the population of the greater region of
Copenhagen. These subjects underwent digital ECG recordings in a general practitioner’s core facility from 2001 to
2010. Data on drug use, comorbidities, and outcomes were collected from Danish registries.Results After a median follow-up period of 5.7 years, 10,766 subjects had developed AF, of whom 1,467 (14%) developed
lone AF. Having a QTc interval lower than the ﬁrst percentile (372 ms) was associated with a multivariate-adjusted
hazard ratio of 1.45 (95% conﬁdence interval: 1.14 to 1.84; p ¼ 0.002) of AF, compared with the reference group
(411 to 419 ms). From the reference group and upward, the risk of AF increased with QTc interval duration in a dose-
response manner, reaching a hazard ratio of 1.44 (95% conﬁdence interval: 1.24 to 1.66, p < 0.001) for those with
QTc intervals 99th percentile (464 ms). The association with respect to longer QTc intervals was stronger for the
outcome of lone AF, as evidenced by a hazard ratio of 2.32 (95% conﬁdence interval: 1.52 to 3.54, p < 0.001) for
having a QTc interval 99th percentile (458 ms).Conclusions In this large ECG study, a J-shaped association was found between QTc interval duration and risk of AF. This
association was strongest with respect to the development of lone AF. (J Am Coll Cardiol 2013;61:2557–64)
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Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CGPL = Copenhagen General
Practitioners’ Laboratory
QTc = heart rate–corrected
QT interval
QTcFram = QT interval
corrected for heart rate
using the Framingham
formula (QTcFram ¼ QT þ
154[1-60/heart rate])
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2558the QTc interval. In addition to
an increased risk of sudden
cardiac death, patients with these
rare syndromes also have a high
prevalence of AF (4,5). However,
whether the duration of the QTc
interval is associated with AF is
unknown.
This study was designed to
investigate the possible associa-
tion of the QTc interval with the
onset of AF in the general pop-
ulation. This could lead to abetter understanding of the pathophysiology underlying AF
and could also allow the development of clinically relevant
prognostic models.Figure 1
Flowchart of Study Population Selection, Showing the
Number of Subjects Excluded for Various Reasons
AF ¼ atrial ﬁbrillation; CGPL ¼ Copenhagen General Practitioners’ Laboratory;
ECG ¼ electrocardiogram; ICD ¼ implantable cardioverter-deﬁbrillator.Methods
Study population. In the greater region of Copenhagen,
Denmark, the vast majority of general practitioners refer
their patients to 1 core facility (the Copenhagen General
Practitioners’ Laboratory [CGPL]) for clinical tests, such as
biochemistry and electrocardiogram (ECG) recordings. The
study population consists of all subjects who underwent
ECG recording at CGPL at the behest of their general
practitioners from 2001 to 2010. Subjects were excluded for
reasons shown in Figure 1.
Further details on the ECG study population, including
a comparison with the general population with respect to the
incidence of AF and mortality rate, are provided in the
Online Appendix.
Because our study was registry based, with no active
participation from study subjects, no approval from an ethics
committee was required according to Danish law. The use of
registry data was approved by the Danish Data Protection
Agency.
Electrocardiography. All ECGs were digitally recorded
and stored in the MUSE Cardiology Information System
(GE Healthcare, Wauwatosa, Wisconsin) and later pro-
cessed using version 21 of the Marquette 12SL algorithm.
With the use of the 12SL algorithm, we excluded ECGs
with ﬁndings not consistent with a valid measurement of the
QTc interval (e.g., AF and branch blocks; see the Online
Appendix for validation and details on this algorithm).
The QT interval was obtained as a representative median
beat from all PQRST complexes in the 12 leads of the 10-s
ECG tracing (see the Online Appendix for details). QT
intervals were corrected for heart rate using the Framingham
linear regression formula (QTcFram ¼ QT þ 154[1-60/
heart rate]) or Bazett’s formula (QTc ¼ QT/RR1/2). Left
ventricular hypertrophy was deﬁned according to Sokolow-
Lyon electrocardiographic criteria as follows: 1) R-wave in
lead V5 or V6> 2.6 mV; or 2) S-wave in lead V1þ R-wave in
lead V5 or V6  3.5 mV.Baseline variables and follow-up. With the use of
Danish registries and a unique personal identiﬁcation
number assigned to all persons with permanent residence
in Denmark, it is possible to follow subjects with respect
to death, emigration, the use of prescription medications,
and any hospital, ambulatory, or emergency department
discharge diagnoses (6–10). With the use of such registry
data and data from biochemical tests conducted at CGPL,
we identiﬁed subjects with the following baseline variables:
hypertension, heart failure, myocardial infarction, valvular
heart disease, diabetes, hyperthyroidism, and treatment with
QT interval–prolonging drugs on the day of ECG recording
(yes or no) (Online Table 1). In brief, hypertension was
deﬁned as present if a subject at some point before study
inclusion was treated simultaneously with at least 2 kinds of
antihypertensive drugs (11). Heart failure was deﬁned as
a combination of a discharge diagnosis of heart failure and
treatment with loop diuretics (11). Myocardial infarction
and valvular heart disease were deﬁned from discharge
diagnoses. Diabetes and hyperthyroidism were deﬁned as
present if a subject at some point before study inclusion had
a discharge diagnosis of diabetes or hyperthyroidism, in case
of a blood sample taken at the behest of a general practi-
tioner indicative of disease, or in case of a purchase of
prescription medication used for management of 1 of the 2
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2559diseases. A hospital, ambulatory, or emergency department
discharge diagnosis of AF or atrial ﬂutter was the primary
event of interest. Lone AF was deﬁned as the occurrence of
AF before the age of 65 years and in the absence of
hypertension, heart failure, myocardial infarction, valvular
heart disease, diabetes, and hyperthyroidism. Detailed
information on the identiﬁcation of covariates and clinical
outcomes in the Danish registries is provided in the Online
Appendix.
Statistical analysis. Age was used as the time scale in all
survival analyses. Events of AF were recorded after the day
of the ﬁrst ECG. Follow-up ended in case of AF, death, or
emigration or on October 8, 2011, which was the end of
complete follow-up data acquisition. Crude incidence rates of
AF per 1,000 person-years were calculated using Poisson
regression. Cox regression was used to assess the association
of QTc interval, measured on the day of inclusion (ﬁrst
ECG), with the instantaneous risk (hazard) of AF. Cox
regression was adjusted for conventional risk factors that were
obtained at the age of inclusion. To provide detailed analysis
of the functional relationship between QTc interval duration
and the risk of AF, we used 2 alternative approaches. First, we
divided the population (or subpopulations) into 9 risk cate-
gories on the basis of the population QTc interval distribu-
tion, with cutoffs at the ﬁrst, ﬁfth, 20th, 40th, 60th, 80th,
95th, and 99th percentiles. In these analyses, the QTc
interval category with the lowest risk of AF was used as the
reference group. Second, to describe the functional rela-
tionship between QTc interval duration and the risk of AF in
a more unbiased way, we also performed restricted cubic
regression spline analysis with 4 knots located at the ﬁfth,
35th, 65th, and 95th percentiles (12).
Subgroup analyses were performed, including an analysis
with lone AF as an outcome. For this analysis, patients with
hypertension, heart failure, myocardial infarction, valvular
heart disease, diabetes, hyperthyroidism, and/or age>65 years
at baseline were excluded. An event (diagnosis) of hyper-
tension, heart failure, myocardial infarction, valvular heart
disease, diabetes, or hyperthyroidism or surpassing 65 years
of age during the follow-up period was considered a com-
peting risk of lone AF, and event time was set to the earliest of
these events. To explore the association of QTc interval and
the risk of AF in patients with cardiovascular disease, another
subgroup analyses was performed including only subjects who
had hypertension, heart failure, myocardial infarction, and/or
valvular heart disease at the age of inclusion. Sensitivity
analyses are described in the Online Appendix.
We considered a 2-tailed p value <0.05 as statistically
signiﬁcant. Proportional hazards assumptions were checked and
accepted for all covariates. All analyses were conducted using
Stata version 12.0 (StataCorp LP, College Station, Texas).Results
Study cohort. The greater region of Copenhagen has
a current population of 1.18 million citizens. Among them,326,959 subjects (about 28%) had 1 or more ECGs recorded
at CGPL during the 10-year period from 2001 to 2010. Of
the subjects referred for ECG recording, a total of 281,277
(86%) fulﬁlled the study inclusion criteria (Fig. 1). Baseline
clinical characteristics of the study population are shown in
Table 1. Follow-up was 100% with regard to clinical end
points, mortality, and emigration.
Risk of AF. TOTAL STUDY POPULATION. The median
follow-up time for the total study population was 5.7 years
(interquartile range: 3.2 to 8.4 years), corresponding to
1,614,832 person-years. During follow-up, 10,766 subjects
developed AF, and 26,974 died. The multivariate-adjusted
analysis exploring the association between categories of QTc
interval duration and the risk ofAF revealed that the risk ofAF
increased in a dose-responsemanner from 420ms and upward
(Fig. 2). Compared with the reference group (40th to <60th
percentile, 411 to 419 ms), the risk of AF reached a hazard
ratio of 1.44 (95% conﬁdence interval: 1.24 to 1.66; p< 0.001)
for those with QTcFram intervals99th percentile (464 ms).
At the lower range of the interval, only subjects with QTcFram
intervals lower than the ﬁrst percentile (372 ms) had
a statistically signiﬁcant increased risk of AF (hazard ratio:
1.45; 95% conﬁdence interval: 1.14 to 1.84, p ¼ 0.002). The
multivariate-adjusted restricted cubic spline analysis conﬁrm-
ed the J-shaped association obtained from the analysis based
on QTc categories (Fig. 3). In this spline-based analysis,
subjects with QTcFram intervals of 404 ms had the lowest risk
of AF, whereas the risk increased for both longer and shorter
QTcFram intervals.
LONE AF. For the lone AF subgroup analysis, 175,738
subjects were included at baseline, and of these, 1,467
developed lone AF. The median follow-up time for the
lone AF model was 4.3 years (interquartile range: 2.1 to
7.0 years), corresponding to 816,322 person-years. This
subgroup analysis revealed that the association between QTc
interval and the outcome of lone AF was stronger compared
with AF, at least for QTc intervals in the upper range
(Figs. 2 and 3).
AF IN PATIENTS WITH CARDIOVASCULAR DISEASE. For the
subgroup analysis of risk of AF in patients with cardiovas-
cular disease, 47,777 subjects were included at baseline,
3,879 developed AF, and the median follow-up time was
5.5 years (interquartile range: 2.9 to 8.3 years), corresponding
to 266,177 person-years. Exploring the association between
QTc interval and the risk of AF in this subgroup revealed
a weaker association with respect to longer QTc intervals
compared with results from the total study population. For
shorter QTc intervals, the association was similar to the
results from the total population (Figs. 2 and 3).
SENSITIVITY ANALYSIS. Fifty-six percent of the study pop-
ulation had available cholesterol proﬁles at baseline. Adding
the total/high-density lipoprotein cholesterol ratio into the
model for this subgroup did not change the pattern of
association (Online Fig. 1). In a time-dependent model in
Table 1 Clinical Characteristics of the Study Population
Characteristic
Overall
(340–492 ms)
(n ¼ 281,277)
Percentiles of QTcFram Interval and Associated Interval Limits
<1st
(372 ms)
(n ¼ 2,652)
1st to <5th
(373–385 ms)
(n ¼ 10,706)
5th to <20th
(386–399 ms)
(n ¼ 38,887)
20th to <40th
(400–410 ms)
(n ¼ 59,343)
40th to <60th
(411–419 ms)
(n ¼ 55,038)
60th to <80th
(420–430 ms)
(n ¼ 57,043)
80th to <95th
(431–446 ms)
(n ¼ 42,533)
95th to <99th
(447–463 ms)
(n ¼ 12,238)
99th
(464 ms)
(n ¼ 2,847)
Age (yrs) 54 (41–65) 38 (28–51) 43 (32–56) 48 (35–61) 51 (39–63) 54 (41–65) 56 (44–67) 58 (47–69) 60 (50–72) 63 (52–75)
Women 157,212 (56%) 667 (25%) 3,516 (33%) 16,937 (44%) 30,687 (52%) 31,325 (57%) 35,404 (62%) 28,303 (67%) 8,434 (69%) 1,939 (68%)
Incident AF during
follow-up
10,766 (4%) 70 (3%) 252 (2%) 1,129 (3%) 1,895 (3%) 1,913 (3%) 2,387 (4%) 2,112 (5%) 799 (7%) 209 (7%)
Crude incidence rate
of AF (per 1,000
person-years) (95% CI)
6.7 (6.5–6.8) 4.6 (3.7–5.9) 4.1 (3.6–4.6) 5.0 (4.7–5.3) 5.5 (5.3–5.8) 6.0 (5.8–6.3) 7.3 (7.0–7.6) 8.7 (8.4–9.1) 11.9 (11.1–12.8) 14.1 (12.3–16.1)
Medical history
Hypertension 44,205 (16%) 163 (6%) 769 (7%) 3,835 (10%) 7,168 (12%) 8,127 (15%) 10,200 (18%) 9,412 (22%) 3,481 (28%) 1,050 (37%)
Heart failure 1,742 (1%) 8 (0%) 21 (0%) 111 (0%) 219 (0%) 263 (0%) 385 (1%) 453 (1%) 192 (2%) 90 (3%)
Myocardial infarction 6,482 (2%) 42 (2%) 140 (1%) 611 (2%) 1,035 (2%) 1,157 (2%) 1,426 (3%) 1,409 (3%) 498 (4%) 164 (6%)
Valvular heart disease 897 (0.3%) 1 (0.0%) 10 (0.1%) 72 (0.2%) 129 (0.2%) 152 (0.3%) 202 (0.4%) 221 (0.5%) 82 (0.7%) 28 (1.0%)
Diabetes 16,367 (6%) 78 (3%) 339 (3%) 1,646 (4%) 2,979 (5%) 3,167 (6%) 3,684 (6%) 3,101 (7%) 1,103 (9%) 270 (9%)
Hyperthyroidism 4,622 (2%) 22 (1%) 132 (1%) 530 (1%) 905 (2%) 879 (2%) 1,034 (2%) 797 (2%) 247 (2%) 76 (3%)
QTc interval–prolonging
drugs on the day
of ECG recording
21,773 (8%) 103 (4%) 501 (5%) 2,192 (6%) 3,886 (7%) 3,944 (7%) 4,757 (8%) 4,211 (10%) 1,642 (13%) 537 (19%)
ECG variables
Heart rate
(beats/min)
69 (62–78) 56 (50–65) 62 (55–72) 67 (59–77) 70 (62–79) 71 (62–80) 70 (64–79) 70 (63–78) 68 (62–76) 66 (60–73)
PR interval (ms) 156 (142–172) 154 (142–172) 154 (140–170) 154 (140–170) 154 (140–170) 154 (142–170) 156 (142–172) 156 (144–172) 160 (146–176) 162 (148–180)
QTcFram interval (ms) 415 (403–428) 367 (362–370) 381 (378–384) 394 (391–397) 406 (403–408) 415 (413–417) 424 (422–427) 436 (433–441) 452 (449–456) 470 (466–476)
QTcFram interval (ms) 416  19 365  6 381  4 394  4 405  3 415  3 425  3 437  4 453  5 472  7
Left ventricular
hypertrophy
12,166 (4%) 235 (9%) 718 (7%) 1,870 (5%) 2,402 (4%) 2,076 (4%) 2,169 (4%) 1,718 (4%) 727 (6%) 251 (9%)
Values are median (interquartile range), n (%), or mean  SD.
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; ECG ¼ electrocardiogram; QTcFram ¼ QT interval corrected for heart rate using the Framingham formula.
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Figure 2 Multivariate-Adjusted Hazard Ratios for AF, Lone AF, and Post-CVD AF by Risk Categories of QTc Intervals
The atrial ﬁbrillation (AF) model and the post–cardiovascular disease (CVD) AF model were adjusted for sex, hypertension, heart failure, myocardial infarction, valvular
heart disease, diabetes, hyperthyroidism, PR interval (low <140 ms, medium 140 to 180 ms, high >180 ms), left ventricular hypertrophy according to the Sokolow-Lyon
electrocardiographic criteria, and treatment with heart rate-corrected QT (QTc) interval–prolonging drugs on the day of inclusion (yes or no). The lone AF model was adjusted for
sex, PR interval (low <140 ms, medium 140 to 180 ms, high >180 ms), left ventricular hypertrophy according to the Sokolow-Lyon electrocardiographic criteria, and treatment
with QTc interval–prolonging drugs at the day of inclusion (yes or no). Age was the time scale in all models. The QTc interval risk category with the lowest risk of AF was chosen as
the reference category in all analysis. The vertical dotted lines represent a hazard ratio of 1. The horizontal solid lines represent 95% conﬁdence intervals. The QT intervals were
corrected for heart rate using either the Framingham formula (QTcFram) or Bazett’s formula (QTcBaz).
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2561which status regarding hypertension, heart failure, myocar-
dial infarction, valvular heart disease, diabetes, and hyper-
thyroidism was updated over time, the association between
longer QTc intervals and the risk of AF was slightly weaker
than the model including only baseline data (Online Fig. 1).
Discussion
In a large primary care population, we investigated the risk
of AF as a function of QTc interval duration and found a
J-shaped association (Figs. 2 and 3).
Because QTc interval prolongation is a well-known
predictor of cardiovascular mortality (2), it is important to
raise the question of whether QTc interval prolongation is
just a marker of cardiac disease, such as ischemic heart
disease and heart failure, and not directly associated with
AF. Therefore, beyond adjusting for the noted comorbid-
ities, we also investigated this aspect by looking at lone AF,that is, younger subjects (<65 years of age) free of cardio-
vascular disease. As noted, we found that the association for
QTc intervals in the longer range was strongest for subjects
who developed lone AF, less so for the whole population,
and weakest, but still present, for the population with
cardiovascular comorbidities. This result indicates that the
QTc interval’s association with AF is not due simply to
confounding by traditional cardiovascular risk factors;
instead, it seems to be due to inherent characteristics or
remodeling of a patient’s cardiac electrophysiology.
All ECGs were analyzed digitally using clinically vali-
dated software, thus avoiding any intraobserver or interob-
server variability. The 12SL algorithm is widely used, has
been approved by the U.S. Food and Drug Administration
for use in pharmaceutical studies, and has been validat-
ed extensively with regard to QT interval measurement
(13–15). Additionally, the 12SL algorithm has recently been
shown to have a much better intrasubject reproducibility
Figure 3 Functional Relationship Between QTc Interval Duration and the Risk of AF, Lone AF, and Post-CVD AF
(A) Multivariate-adjusted restricted cubic spline analysis showing the hazard ratio of atrial ﬁbrillation (AF) as a function of the QT interval corrected for heart rate using the
Framingham formula (QTcFram) with 95% conﬁdence limits (dashed lines) superimposed on a histogram of the population QTcFram interval distribution. (B) Subgroup analysis for
the outcomes of lone AF and post–cardiovascular disease (CVD) AF. Adjustment factors are described in Figure 2. The horizontal dotted lines represent a hazard ratio of 1.
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2562than manual QTc measurement (15). In addition, our
algorithm for excluding ECGs not suited for measurement
of QTc interval was found to be valid (Online Appendix).
We applied the Framingham formula for heart rate
correction of the QT interval because this formula is widely
used, because it is based on empirical data from a large
population sample rather than on hypothetical reasoning
(16), and because linear regression functions rather than
Bazett’s formula are recommended in recent guidelines (17).
However, for comparability with previous studies of QTc
interval, we also provide results for the widely used Bazett’s
formula. Using the 2 different formulas resulted in similar
conclusions (Fig. 2).
Although the present study was not designed to evaluate
the biology linking QTc interval duration and AF, our
data raise several interesting pathophysiological questions.
To our knowledge, there is no deﬁnitive evidence of direct
proportionality between atrial and ventricular action poten-
tial duration (closely correlated with the QTc interval).
However, messenger ribonucleic acid expression studies have
shown that the expression of important ion channel com-
plexes involved in cardiac repolarization is very similar in
atrial and ventricular tissues (18,19), and one must assume
that atrial and ventricular repolarization duration are related.
The prevailing conceptual model for AF genesis describes
shortened atrial action potential duration as a substrate for
multiple-circuit reentry excitation in the atria as the mech-
anism of arrhythmia (20). In support of this model, many
drugs used for rhythm control or termination of AF prolong
the action potential duration and, with this, the QTc interval
(21). This is in line with our data showing that subjects with
QTc intervals at the very short end of the normal range have
increased risk of AF and also that patients with the rare
short-QT syndrome have a high prevalence of AF (5). In
contrast, our data, which mainly show an increased risk of
AF with longer QTc intervals, are in conﬂict with the
prevailing theory of AF genesis. We speculate thata mechanism of “atrial torsades de pointes” could mediate
the susceptibility to AF, similar to the mechanism thought
to underlie ventricular arrhythmias in long-QT syndrome.
In support of this hypothesis, a recent mouse model of long-
QT syndrome type 3 has indicated that a substrate of pro-
longed atrial action potential duration and the occurrence of
triggers in form of early after-depolarizations can promote
AF (22). In addition, it has been documented that patients
with long-QT syndrome, not only have prolonged atrial
action potential duration (23), but also have a much higher
prevalence of early-onset lone AF compared with the
background population (4). In addition, we recently showed
that patients with early-onset lone AF carry a high preva-
lence of genetic variants previously associated with long-QT
syndrome type 3 (24). Finally, both patients with AF
after heart failure and those with lone AF remote from
arrhythmic episodes seem to have prolonged atrial refractory
periods obtained by intracardiac recordings compared with
controls (25,26). Accordingly, our data indicate that both
shortened and prolonged action potential duration could be
a substrate for AF not only in rare cases of short-QT and
long-QT syndromes but also in the general population.
Interestingly, it has lately been documented that QTc
interval prolongation is associated with an increased risk of
stroke (27,28). However, the mechanism for this association
has not yet been identiﬁed. Our data indicate that AF could
be the link between QTc interval prolongation and stroke.
Study limitations. For data on morbidity, mortality, and
medication use, we relied on Danish registries, and for some
diagnoses, we do not know their validity in these registries.
However, with regard to the most important diagnoses used
in this study, these have been validated. Accordingly, the
Danish registry-based diagnosis of AF has recently been
found to have a positive predictive value of 93% for elec-
trocardiographically documented AF by manual review of
patient records (29), and the diagnosis has additionally been
found to be valid in a number of other studies (30–32). This
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of hypertension (11), heart failure (33), and myocardial
infarction (34).
Although we found the strongest association with respect
to the outcome of lone AF, we cannot exclude some residual
confounding, because we lack information on important
anthropometric data on our study population, such as body
mass index, blood pressure, and smoking status. However,
we were able to adjust for several cardiovascular risk factors
and diseases that are likely intermediate phenotypes for the
possible confounding effect of body mass index, blood
pressure, and smoking status on the association between
QTc interval duration and the risk of AF. We adjusted for
treatment with antihypertensive medication as a proxy for
hypertension, and by using this approach, we cannot exclude
residual confounding by untreated hypertension. However,
we believe that our deﬁnition of hypertension might be as
good as controlling for a single blood pressure measurement,
as done in many cohort studies, because such a blood
pressure measurement is not always a good estimate of a
subject’s true resting blood pressure (35–37). Additionally,
we developed a model looking at the subgroup with
cholesterol level measurements and found that adding the
total/high-density lipoprotein cholesterol ratio to the model
for this subgroup did not change the pattern of association
(Online Fig. 1). Moreover, applying a time-dependent
model in which statuses regarding covariates were updated
over time only attenuated the association slightly with
respect to longer QTc intervals (Online Fig. 1).
We observed an increased incidence rate of AF in the
electrocardiographic study population compared with the
general population (6.7 vs. 5.3 per 1,000 person-years,
respectively) (Online Appendix), indicating a slight selec-
tion bias with regard to the outcome of AF. However, our
incidence rate of AF is in line with those from previous
reports (38,39). Additionally, the study population was not
much sicker than the general population, as demonstrated by
an only slightly increased mortality rate in the study pop-
ulation compared with the general population (16.7 vs.
16.0 per 1,000 person-years, respectively; see the Online
Appendix). Although our study population represents
a sample with a higher rate of the outcome in question (AF)
and a slightly higher mortality, most nonopportunistic
cohort studies likely suffer from the opposite issue in the
form of an often pronounced healthy responder bias (40,41).
Finally, because our population was recruited from a
mainly white population, it is uncertain whether our ﬁndings
can be extrapolated to other ethnicities.
Conclusions
The present study population is the largest primary care
population studied to date, encompassing about a third of
the population in a capital region, with high-quality digital
ECGs and almost complete follow-up. In this population,
we found a robust J-shaped association between QTcinterval duration and the occurrence of AF. With regard to
the upper range of the QTc interval, this association was
most pronounced for lone AF.Reprint requests and correspondence: Dr. Jonas Bille Nielsen,
Department of Cardiology, Rigshospitalet, Laboratory for Molec-
ular Cardiology, 9312, Juliane Mariesvej 20, 2100 Copenhagen Ø,
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APPENDIX
For an expanded Methods and Results section, as well as a supplemental
table and ﬁgure, please see the online version of this article.
